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Human papillomaviruses (HPVs) are small DNA viruses that
comprise over 100 types. Some of them, so-called high-risk HPVs,
are oncogenic. They are aetiologically linked with cervical carcin-
oma (CC) and probably also with some other human cancers (zur
Hausen, 1996). The type most frequently associated with human
cancer is HPV16. It is detected in 50–60% of CC cases (Bosch 
et al, 1995). 
Worldwide, CC is the second most common malignancy in
women, with approximately 500 000 new cases diagnosed each
year (Parkin et al, 1993). The mortality rate is about 60%. Because
of the strength of the CC–HPV association, both prophylactic and
therapeutic vaccines against HPVs are being developed (Vonka,
1996; Jochmus et al, 1999; van Driel et al, 1999). The only HPV
proteins expressed in CC, as well as in cells transformed in vitro,
are the non-structural proteins E6 and E7, which are involved both
in the malignant transformation of cells and in maintenance of the
transformation state (Galloway and McDougall, 1996). The
expression levels of E6 and E7 correlate with their oncogenic
activity (Liu et al, 1995; Trujillo and Mounts, 1996). These
proteins can serve as targets of immune responses (Chen et al,
1991, 1992) induced by specific therapeutic vaccines. 
Although the first clinical studies designed to cure CC by
immunological intervention have already been started (McNeil,
1997a, 1997b), intensive search is still going on for suitable labor-
atory models in which the various parameters of immunity against
HPV-induced tumours could be investigated. We reported previ-
ously the isolation of oncogenic Syrian hamster cell lines after
transfection of secondary kidney cells with HPV16 E6/E7 genes
and activated H-ras oncogene and described specific immune
reactions (both humoral and cell-mediated) in animals bearing
tumours elicited by these cells (Kitasato et al, 1996). In a subse-
quent study (Bubeník et al, 1996), protection against challenge
with these cells was induced by inoculation of irradiated homolo-
gous tumour cells, and this immunity was significantly enhanced
by the simultaneous administration of mouse interleukin-2 (mIL-
2); we had previously shown that mIL-2 was as effective in the
hamster system as in the mouse system (Sobotková et al, 1996). In
other experiments we presented evidence that protection against
tumour development could also be induced by the simultaneous or
preceding inoculation of HPV16-transformed hamster cells
expressing the herpes simplex virus thymidine-kinase gene if
followed by treatment with ganciclovir (GCV) (Vonka et al, 1998).
Finally, we were able to induce partial immunity against these
cells by immunization with plasmids carrying the HPV16 E6/E7
genes or activated H-ras oncogene (Smahel et al, 1999). 
In an effort to develop a system free of the major disadvantages
of Syrian hamsters, i.e. their ‘semisyngeneity’ and a lack of reli-
able reagents needed for analysis of the immune responses, we
recently established several HPV16-transformed mouse C57BL/6
cell lines. A protocol similar to that employed in the Syrian
hamster system was used. In the present report we describe some
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Summary In the endeavour to develop a model for studying gene therapy of cancers associated with human papillomaviruses (HPVs),
mouse cells were transformed with the HPV type 16 (HPV16) and activated H-ras oncogenes. This was done by contransfection of plasmid
p16HHMo, carrying the HPV16 E6/E7 oncogenes, and plasmid pEJ6.6, carrying the gene coding for human H-ras oncoprotein activated by
G12V mutation, into secondary C57BL/6 mouse kidney cells. An oncogenic cell line, designated MK16/1/IIIABC, was derived. The epithelial
origin of the cells was confirmed by their expression of cytokeratins. No MHC class I and class II molecules were detected on the surface of
MK16/1/IIIABC cells. Spontaneous metastases were observed in lymphatic nodes and lungs after prolonged growth of MK16/1/IIIABC-
induced subcutaneous tumours. Lethally irradiated MK16/1/IIIABC cells induced protection against challenge with 105 homologous cells, but
not against a higher cell dose (5 ´ 105). Plasmids p16HHMo and pEJ6.6 were also used for preventive immunization of mice. In comparison
with a control group injected with pBR322, they exhibited moderate protection, in terms of prolonged survival, against MK16/1/IIIABC
challenge (P < 0.03). These data suggest that MK16/1/IIIABC cells may serve as a model for studying immune reactions against HPV16-
associated human tumours. © 2001 Cancer Research Campaign http://www.bjcancer.com
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of the basic properties of the transformed mouse cells and present
data from immunization/challenge experiments designed to induce
protection against these cells. 
MATERIAL AND METHODS 
Animals and cells 
C57BL/6 mice (H-2b) (Charles Rivers, Germany) were used in this
study. Animals were maintained under standard conditions and
UKCCCR guidelines for the care and treatment of animals in
experimental neoplasia were observed. Secondary cell cultures
were prepared from the kidneys of an adult animal and grown in
Dulbecco’s Modified Eagle’s Medium (D-MEM) (Sevac, Prague)
supplemented with 10% fetal calf serum, 2 mM L-glutamine, 100
U ml–1 penicillin and 100 mg ml–1 streptomycin. CaSki cells have
been derived from HPV16-positive human cervical cancer (Baker
et al, 1987). HEF cells are spontaneously immortalized cells
isolated from a hamster embryo fibroblast culture (Kutinová
1975). TC-1 cells have been prepared by transformation of
C57BL/6 primary mouse lung cells with HPV-16 E6/E7 onco-
genes and activated H-ras (Lin et al, 1996) and were kindly
provided by Dr TC Wu (Johns Hopkins University, Baltimore). All
cell lines were grown in EPL medium (Sevac, Prague) (Kutinová
and Vonka, 1978).
Plasmids 
Plasmids p16HHMo (Vousden et al, 1988), pEJ6.6 (Shih and
Weinberg, 1982) and pAG60 (Colbere-Garapin et al, 1981),
carrying, respectively, the HPV16 E6/E7 oncogenes, the human H-
ras oncogene activated by G12V mutation, and the neomycin
resistance gene, were kindly donated by Drs K Vousden (Ludwig
Institute for Cancer Research, London), M Dürst, and F Rössl
(both DKFZ, Heidelberg), respectively. We compared the
sequences of human and mouse H-ras proteins and found no
mismatch. Therefore, the G12V mutation represents the only
difference between the normal mouse H-ras protein and the human
H-ras oncoprotein expressed from pEJ6.6. 
Plasmids to be used in immunization experiments (see below)
were propagated in Escherichia coli, XL1-blue strain, in Terrific
Broth Medium with 100 mg ml–1 of ampicillin added. Plasmid
DNA was extracted by alkaline lysis followed by CsCl gradient
centrifugation. Purified DNA was dissolved in phosphate-buffered
saline (PBS) and stored at–20˚C. 
Cell transformation 
Plasmids pEJ6.6 and p16HHMo were cotransfected, along with
pAG60, into secondary mouse kidney cells. In the transfection, the
lipofection reagent DOTAP (Boehringer, Mannheim) was used,
following the manufacturer’s instructions. Lines of transformed
cells were established as described previously (Kitasato et al, 1996). 
Analysis of nucleic acids 
DNA was extracted from cell lines by the sodium dodecyl sulphate
(SDS)-proteinase K-phenol-chloroform method (Blin and
Stafford, 1976). Total RNA was isolated using the RNA Blue
Reagent (Top-Bio, Prague) (Chomczynski, 1993). Southern blot
hybridization and the reverse transcriptase-polymerase chain
reaction (RT-PCR) were performed as described previously
(Kitasato et al, 1996). 
Immunoblotting 
Material for the detection of the H-ras oncoprotein was prepared
by lysis of cells with RIPA buffer (150 mM NaCl, 1% NP-40,
0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris, pH 7.5).
Secondary mouse kidney cells (MKC) were used as a negative
control. Cell monolayers in 150 cm2 bottles were washed with
PBS and placed on ice. One millilitre of RIPA buffer precooled at
+4˚C was added per bottle and the cells were incubated on ice for
30 min with occasional rocking. Lysed cells were collected by
scraping and the cell debris in the lysis buffer was transferred into
an Eppendorf tube and spun at 10 000 g for 10 min at +4˚C.
Samples were further analysed by 10% SDS-PAGE. The proteins
separated were electroblotted onto a nitrocellulose membrane
and incubated, in PBS, with anti-pan-rasVal-12 mouse antibody
(Calbiochem, La Jolla, CA) diluted in 10% non-fat milk for 2
hours at room temperature or overnight at +4˚C. The blots were
then washed 5 ´ 5 min with PBS/0.1% Tween, secondary perox-
idase-labelled anti-mouse antibody was added, and the mixture
was kept for 1 hour at room temperature. The blots were washed 8
´ 5 min with PBS/0.1% Tween and specific antigens were detected
using the ECL Plus system (Amersham, Little Chalfont, England). 
Flow cytometry 
Cells were harvested with trypsin and washed twice with PBS. For
detection of MHC class I molecules, cells were incubated with
anti-mouse H-2Kb/H-2Db monoclonal antibody (clone 28-8-6,
Pharmingen, San Diego, CA) or with isotype control antibody
(Sigma, St. Louis, MO) at 4˚C for 30 min, washed and incubated
with FITC-conjugated goat anti-mouse Ig antibody (Pharmingen)
at 4˚C for 30 min. Expression of MHC class II molecules was
detected with FITC-labelled anti-mouse I-Ab monoclonal antibody
(clone AF6-120.1, Pharmingen). 
Immunocytochemistry 
MK16/1/IIIABC and TC-1 cells grown on plastic dishes were
washed with PBS and fixed in a cold mixture of methanol and
acetone (1:1 by volume) for 10 min. Cytokeratins were detected by
standard immunostaining with antikeratin monoclonal antibodies
C-11 (binds keratins 4, 5, 6, 10, 13 and 18) and C-22 (recognizes
keratins 5 and 8) (Bartek et al, 1991; Bartkova et al, 1991).
Antibody DC-10 (Lauerova et al, 1988), which reacts with human
keratin 18 only, was used as a negative control. Peroxidase- or
FITC-conjugated rabbit antisera against mouse immunoglobulins
(DAKO, Glostrup, Denmark), diluted 1:50 and 1:20, respectively,
were used as secondary antibodies. Where the peroxidase conjug-
ate was employed, positive cells were stained with DAB (Sigma)
and nuclei were counterstained with haematoxylin. 
Tumour induction and growth 
Cells were harvested with trypsin, washed three times with PBS and
injected s.c. (0.2 ml) in the back of C57BL/6 mice. Tumour devel-
opment was regularly monitored. In a DNA immunization experi-
ment (see below), survival of tumour-bearing mice was recorded. 
Student’s t-test was used for statistical analysis. 376 M S
v
mahel et al 
British Journal of Cancer (2001) 84(3), 374–380 © 2001 Cancer Research Campaign
Tumour metastases 
Mice were inoculated with 105, 106 or 107 MK16/1/IIIABC cells.
When their tumours reached approximately 1.5 cm in diameter, the
mice were humanely killed and autopsied. Their lymph nodes,
lungs, liver, heart and brain were examined histologically for the
presence of spontaneous metastases. The organs were fixed in 10%
neutral buffered formalin and embedded in paraffin. Sections were
stained with haematoxylin and eosin. 
Immunization with irradiated cells 
Male mice, 6–8 weeks old, were immunized with two doses of
irradiated (200 Gy) MK16/1/IIIABC cells: 106 cells were injected
on day 0 and 107 cells on day 34. 20 days later, groups of 5 animals
were challenged s.c. with 105 or 5´105 MK16/1/IIIABC cells,
injected at a body site different from that used in immunization.
Nonimmunized mice served as controls. 
DNA immunization 
Male mice, 6–8 weeks old, received three 100 mg i.m. doses of
plasmid DNA in 50 ml PBS at 3-week intervals. Plasmid pBR322
served as a negative control. 10 days after the third immunization
dose, groups of 8–9 animals were challenged s.c. in the back with
104 MK16/1/IIIABC cells. 
Chemicals 
Cyclophosphamide (Orion Corporation Farmos, Turku, Finland)
was used for treating some of the mice (300 mg kg–1 body weight)
prior to their inoculation with MK16/1 or MK16/1/IA cells. 
RESULTS 
Establishment of oncogenic mouse cell lines 
Secondary kidney cells derived from C57BL/6 mice were
contransfected with the following mixture of plasmids:
p16HHMo, carrying the HPV16 oncogenes E6 and E7; pEJ6.6,
carrying the activated human H-ras oncogene, and pAG60,
carrying the neomycin resistance gene. Following selection with
the neomycin analogue G418 (200 mg ml–1), a cell line designated
MK16/1 was established. These cells (3.3 ´ 106) were inoculated
s.c. into 3-week-old mice. Tumours developed in all 5 animals
treated 1 day before inoculation with cyclophosphamide, but not in
any of 8 cyclophosphamide-untreated mice. Several cell lines were
derived from the tumours and one of them, MK16/1/IA, was inocu-
lated (2 ´ 106 cells) into 3–4-month-old mice treated or untreated
with cyclophosphamide. In this case, tumours developed not only
in the treated animals but also in 2 of 3 untreated mice. From one
of these, an MK16/1/IIAB cell line was isolated. These cells were
again injected into untreated mice and several cell lines were
derived from different tumours. For subsequent experiments the
most oncogenic cell line, MK16/1/IIIABC, was selected. In
different experiments 1 TID50 dose ranged from 103.5 to 104.5,
depending on the age and sex of animals. The results of a repre-
sentative experiment are shown in Figure 1. 
The tumours induced derived from low-differentiated epitheloid
cells (Figure 2A). As angiogenesis in the tumours was low, large
necroses were recorded in their centres (not shown). Despite
infrequent invasive growth and the relatively rarely observed
angioinvasivity of the MK16/1/IIIABC tumours (not shown),
metastases were found in draining lymphatic nodes (11–25%) and in
the lungs (75–80%) (Figure 2B) after prolonged growth (7 weeks) of
subcutaneous tumours induced by administration of 105, 106 or 107
of MK16/1/IIIABC cells. This metastasizing activity apparently did
not depend on the number of cells inoculated. Histological examinat-
ion did not detect metastases in the liver, spleen, heart or brain.
Nucleic-acid analysis of transformed cells 
From the cell lines MK16/1, MK16/1/IA, MK16/1/IIAB and
MK16/1/IIIABC, DNA and RNA were isolated. Southern blot
hybridization of the DNAs, digested with the BamHI restriction
enzyme, was performed using a 32P-labelled probe specific for the
HPV16 E6 gene (Figure 3A). Several bands were detected, with
the band pattern being the same for all samples. This indicated
stable integration of the viral DNA and a clonal origin of the cell
lines. 
Reverse-transcriptase PCR was used to examine unspliced and
spliced forms of the E6/E7 transcripts (Figure 3B). Both unspliced
E6 (PCR product, 420 bp) and spliced E6*I (238 bp) and E6*II
(121 bp) forms were detected in all cell lines, with the unspliced
E6 and spliced E6*I predominating. No marked differences among
the different MK16/1 lines were observed. 
Detection of activated H-ras by immunoblotting 
Expression of the mutated H-ras oncoprotein in MK16/1/IIIABC
cells was tested by immunoblotting (Figure 3C). Antibody specific
for this protein detected one protein band corresponding in size
(21 kDa) to the ras product. In secondary mouse kidney cells used
as a negative control, only nonmutated H-ras protein was demon-
strated with anti-pan-ras monoclonal antibody (Calbiochem) (data
not shown). 
Immunocytochemical detection of cytokeratins 
To confirm the epithelial origin of MK16/1/IIIABC cells, expres-
sion of cytokeratins was tested. Simultaneously, TC-1 cells (Lin 
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Figure 1 Oncogenicity of MK16/1/IIIABC cells. Five-week-old female mice
(n = 6) were inoculated s.c. with 104, 105 or 106 MK16/1/IIIABC cells HPV-transformed mouse cells 377
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et al, 1996), also transformed by HPV16 E6/E7 and activated 
H-ras oncogenes, were analysed. MK16/1/IIIABC cells showed
strong positive peroxidase staining with C-11 and C-22 antibodies,
whereas the DC-10 antibody only produced a nonspecific back-
ground reaction and very weak, diffuse colouring without 
any apparent filamentous network. Immunofluorescence results
A B
Figure 2 Histological examination of MK16/1/IIIABC tumours. Mice were s.c. injected with 106 MK16/1/IIIABC cells and humanely killed after 56 days. Sections
of a paraffin-embedded primary s.c. tumour (A) (´150) and lung with nodular metastasis (B) (´ 90) were stained with haematoxylin and eosin 
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Figure 3 (A) Detection of integrated HPV16 DNA by Southern hybridization. Cellular DNAs were digested with BamHI, separated electrophoretically on 1%
agarose gel, and blotted onto nylon membrane. A fragment excised from the HPV16 E6 gene (HPV16 nt 24–654) was 32P-labelled and hybridized with
membrane at 65˚C for 16 hours. (B) Detection of E6/E7 transcripts by RT-PCR. Complementary DNA prepared from total RNA was amplified with HPV16
E6/E7-specific primers. The products were analysed on 3% agarose gel. Three forms of transcript were detected: E6 (420 bp), E6*1 (238 bp), and E6*II
(121 bp). The smallest product, E6*II, was demonstrated in all samples but is poorly visible on the picture. (C) Detection of activated H-ras by immunoblotting.
Whole-cell lysates were boiled in electrophoresis sample buffer, separated by 10% SDS-PAGE and transferred onto a nitrocellulose membrane. Activated H-ras
was detected with mouse monoclonal anti-pan-rasVal-12 antibody. Secondary MKC were used as a negative control 378 M S
v
mahel et al 
British Journal of Cancer (2001) 84(3), 374–380 © 2001 Cancer Research Campaign
confirmed the above findings, i.e. there was strong fluorescence of
keratin filaments with the C-11 (Figure 4) and C-22 (not shown)
antibodies, while the DC-10 monoclonal antibody was completely
negative. TC-1 cells exhibited only a diffuse background perox-
idase staining with C-22 antibody but no filamentous network 
was seen; the C-11 and DC-10 antibodies gave negative staining.
Immunofluorescence examination of TC-1 cells gave negative
reactions with all of the antibodies tested. 
Testing for MHC class I and class II by flow cytometry 
MHC class I and class II expression on MK16/1/IIIABC cells was
examined by flow cytometry. As positive controls, secondary
MKC and splenocytes were used, respectively. For comparison,
TC-1 cells that had been reported to express MHC class I but not
class II molecules were also stained. While secondary MKC and
TC-1 cells were shown to contain MHC class I molecules, no
MHC class I expression was detected on MK16/1/IIIABC cells
(Figure 5). Both TC-1 and MK16/1/IIIABC cells were MHC class
II negative (Figure 5). 
Induction of antitumour immunity by immunization with
irradiated cells 
Lethally irradiated MK16/1/IIIABC cells were administered as
described in Materials and Methods to induce protection against
Figure 4 Immunofluorescence visualization of keratin network in
MK16/1/IIIABC cells by C-11 monoclonal antibody (´ 480). Note almost
homogeneous distribution of simple epithelial keratins in all cells 
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Figure 5 Detection of MHC class I and class II molecules by flow
cytometry. MK16/1/IIIABC and TC-1 cells were stained with specific
monoclonal antibodies (open histograms) or with isotype control antibodies
(filled histograms). Secondary MKC or splenocytes were stained as positive
controls 
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Figure 6 (A) Tumour formation after immunization with irradiated MK16/IIIABC cells. Mice were immunized s.c. on aday 0 with 106 cells and on day 34 with
107 cells. 20 days later the animals were challenged with 105 or 5 ´1 05  homologous cells. Non-immunized mice served as a control. (B) Survival of mice after
immunization with plasmid p16HHMo or pEJ 6.6. Mice were injected i.m. with 100 mg of plasmid DNA on days 0, 21 and 42. Plasmid pBR322 was administered
as a negative control. On day 52 the animals were challenged s.c. with 104  MK16/1/IIIABC cells. Tumours developed in all mice. The mean survival time of
animals immunized with p16HHMo or pEJ6.6 was significantly prolonged (P < 0.03) in comparison with pBR322-treated animalsHPV-transformed mouse cells 379
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MK16/1/IIIABC challenge. This vaccination completely protected
mice challenged with the lower dose (105) of tumour cells. When
animals were challenged with the higher dose (5 ´105), immuniza-
tion only delayed the appearance of some tumours (Figure 6A),
but the difference was not significant in comparison with control
mice. 
DNA immunization against tumours 
Plasmids p16HHMo and pEJ6.6, used for malignant transforma-
tion of mouse kidney cells, were each tested as a prophylactic
DNA vaccine. The immunization effect in mice challenged with
104 MK16/1/IIIABC cells was weak. Tumours formed in all
animals, but some inhibition of tumour growth was recorded in the
immunized mice and both plasmids prolonged their survival as
compared with control, nonimmunized or pBR322-treated
animals (Figure 6B). This difference was statistically significant
(P< 0.03). 
DISCUSSION 
An oncogenic cell line, MK16/1/IIIABC, was obtained by trans-
formation of secondary mouse kidney cells with the HPV16 E6/E7
and the mutated human H-rasoncogenes. The expression of activ-
ated H-ras in the cells was demonstrated by immunoblotting.
Because of lack of reliable reagents, the E6 and E7 proteins were
not detected. However, we assume they were also produced,
because we showed the presence of unspliced and two spliced
mRNAs that serve as transcripts for expression of both the E6 and
E7 proteins. Moreover, it is reasonable to assume that without
E6/E7 production oncogenic transformation of secondary mouse
kidney cells would not have been achieved. 
At present, TC-1 cells are increasingly utilized for the testing of
anti-HPV therapeutic vaccines. Our MK16/1/IIIABC cells were
obtained by transformation with the same oncogenes as TC-1 cells
had been. Both cell lines originated from C57BL/6 mice; still,
there are considerable differences between them. MK16/1/IIIABC
were derived from secondary kidney cells, they have epitheloid
morphology and strongly express a variety of cytokeratins, while
TC-1 cells have been obtained from a lung cell culture, show
fibroblastoid morphology and do not express any of the keratins
tested in the present series of experiments. Furthermore,
MK16/1/IIIABC cells are MHC class I-negative, while TC-1 cells
are MHC class I-positive. Finally, subcutaneous tumours induced
by MK16/1/IIIABC cells exhibited a strong metastatic potential
(spontaneous lung metastases were observed in about 75% of
tumour-bearing animals), while spontaneous metastases are
extremely rare in animals with tumours formed after inoculation
with TC-1 cells. Because of the latter two characteristics,
MK16/1/IIIABC cells may serve as a highly suitable model for
studying immune reactions against HPV16-associated human
tumours. It should be remembered that in about 70% of CC the
production of MHC class I molecules is downregulated and these
patients have a worse prognosis (Connor et al, 1993; Keating et al,
1995). It has also been reported that MHC class I expression in
metastases is lower than in primary tumours (Cromme et al, 1994). 
We had previously shown in a hamster model that protection
against tumour cells expressing HPV16 E6/E7 and activated H-ras
oncoproteins could be induced by vaccination with plasmid DNA
carrying either the E6/E7(p16HHMo) or activated H-ras(pEJ6.6)
oncogenes (Smahel et al, 1999). Such immunization reduced
tumour incidence from the 40–50% seen in the control group inocu-
lated with pBR322 to about 10–20%. In the present model we
attempted to immunize mice with the same plasmids following the
same immunization scheme. However, the resulting protection
was rather weak. We only recorded differences in tumour size,
time of the appearance of tumours and length of survival of the
animals, but not in the frequency of tumours formed. This might
have been due to the properties of the challenging cells (no MHC
class I and class II molecules, a low level of expression of E6/E7
and/or H-rasgenes) and/or a low capability of C57BL/6 mice to
mount an immune response against these oncoproteins under the
experimental conditions used. However, other factors might also
have been involved. 
As MK16/1/IIIABC cells are both MHC class I and class II
negative, cytotoxic CD4+ and CD8+ T cells could not be responsible
for the protection against the MK16/1/IIIABC challenge.
However, it has been suggested that CD4+ T helper cells play the
central role in the immune response against tumour cells (Hung et
al, 1998; Mumberg et al, 1999). This response was mediated by
activated macrophages and eosinophils (Hung et al, 1998) or by
indirect effects of IFN-g (Mumberg et al, 1999). We suppose that
similar mechanisms might also be induced in our tumour system. 
To summarize, we isolated a line of oncogenic, HPV16-
transformed epitheloid mouse cells, free of MHC class I mole-
cules, which metastasize spontaneously. In the present study we
only managed to induce weak protection against these cells,
whether by immunization with DNA coding for E6/E7 or H-ras
oncoproteins, or by vaccination with irradiated homologous cells.
Therefore, we are presently trying to apply approaches that might
enhance immunity against tumour cells without MHC class I
expression. These experiments have already been started and some
results have been reported (Bubeník et al, 1999). 
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